Colomb E, Nguyen T D, Béchetoille A, Dascotte J C, Valtot F, Brézin A P, Berkani M, Copin B, Gomez L, Polansky J R, Garchon H J
INSERM U25, Paris, France.
Clin Genet. 2001 Sep;60(3):220-5. doi: 10.1034/j.1399-0004.2001.600308.x.
Primary open-angle glaucoma (POAG) is a highly prevalent optic neuropathy and a major cause of irreversible blindness, with elevation of intraocular pressure (IOP) being a primary risk factor. The trabecular meshwork-inducible glucocorticoid response (TIGR)/MYOCILIN (MYOC) gene coding region is mutated in 3-4% of POAG patients. Here, in a retrospective study of 142 POAG patients, we evaluated the influence on glaucoma phenotype of a novel biallelic polymorphism (-1000C/G) located in the upstream region of the MYOC gene. Allele frequencies were similar among patients and controls. However, the G allele (frequency 17.6%), also designated as MYOC.mt1, was associated with an increased IOP (+4.9 mmHg, p=0.0004) and a more damaged visual field (p=0.02). Both effects were predominant in females. Moreover, whereas IOP in MYOC.mt1 noncarriers decreased very markedly to the normal range between diagnosis and inclusion in the study (p=3 x 10(-5) in both males and females), reflecting successful therapy, it decreased less noticeably in MYOC.mt1+ male patients (p=0.005) and not at all in MYOC.mt1+ female patients. MYOC.mt1 appears therefore to be an indicator of poor IOP control and greater visual field damage in diagnosed POAG patients, potentially due to a lack of response to therapeutic intervention. Its typing might help in the selection of treatment paradigms for the management of POAG patients.
原发性开角型青光眼(POAG)是一种高度常见的视神经病变,也是不可逆性失明的主要原因,眼压升高是主要危险因素。在3%-4%的POAG患者中,小梁网诱导糖皮质激素反应(TIGR)/肌纤凝蛋白(MYOC)基因编码区发生突变。在此,我们对142例POAG患者进行回顾性研究,评估位于MYOC基因上游区域的一种新型双等位基因多态性(-1000C/G)对青光眼表型的影响。患者和对照组的等位基因频率相似。然而,G等位基因(频率为17.6%),也被指定为MYOC.mt1,与眼压升高(+4.9 mmHg,p=0.0004)和视野损伤更严重(p=0.02)相关。这两种效应在女性中更为明显。此外,MYOC.mt1非携带者的眼压在诊断至纳入研究期间显著下降至正常范围(男性和女性p均为3×10⁻⁵),反映出治疗成功,而MYOC.mt1阳性男性患者眼压下降不太明显(p=0.005),MYOC.mt1阳性女性患者眼压则完全没有下降。因此,MYOC.mt1似乎是已确诊POAG患者眼压控制不佳和视野损伤更严重的一个指标,可能是由于对治疗干预缺乏反应。对其进行分型可能有助于为POAG患者选择治疗方案。